BidaskClub upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a research note issued to investors on Tuesday, January 16th.
A number of other equities research analysts have also issued reports on the company. Zacks Investment Research upgraded Galapagos from a sell rating to a hold rating in a research note on Wednesday, October 11th. BTIG Research restated a buy rating and set a $118.00 price objective on shares of Galapagos in a research note on Monday, November 20th. Stifel Nicolaus restated a buy rating and set a $120.00 price objective on shares of Galapagos in a research note on Sunday, October 29th. ValuEngine lowered Galapagos from a hold rating to a sell rating in a research note on Friday, December 1st. Finally, Morgan Stanley reiterated an overweight rating and issued a $123.00 target price (up previously from $92.00) on shares of Galapagos in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $111.00.
Galapagos (NASDAQ:GLPG) opened at $108.83 on Tuesday. The firm has a market capitalization of $5,543.47, a PE ratio of -118.29 and a beta of 1.85. Galapagos has a 12-month low of $67.26 and a 12-month high of $121.09.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.